Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2022-05-19 Annual Report
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
Annual Report 2021
Annual Report Classification · 100% confidence The document is explicitly titled 'Vivoryon Therapeutics N.V. Annual Report 2021'. It contains comprehensive sections including an executive management board report, financial review, corporate governance, and financial statements for the fiscal year ended December 31, 2021. It meets the criteria for a full annual report as it provides detailed financial and operational performance data for the year. FY 2021
2022-05-19 English
Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
AGM Information Classification · 98% confidence The document explicitly announces that Vivoryon Therapeutics N.V. will hold its 'Annual General Meeting on June 22, 2022'. The content details the date, location, and agenda items, including the re-appointment of board members. This directly corresponds to the definition of AGM Information (AGM-R). Although it is a news release announcing the meeting, the core subject matter is the AGM itself, making AGM-R the most specific classification over a general Regulatory Filing (RNS) or Report Publication Announcement (RPA), especially since the document provides substantial detail about the meeting's purpose (board appointments).
2022-05-11 English
Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
AGM Information Classification · 98% confidence The document explicitly announces that Vivoryon Therapeutics N.V. will hold its 'Annual General Meeting on June 22, 2022'. It details the agenda items, which include the re-appointment and proposed appointment of Non-Executive Board members, and provides context about the candidates. This content directly relates to the preparation for and subject matter discussed at an AGM. Therefore, the classification should be AGM Information (AGM-R). It is not a proxy statement (PSI) because it is an announcement about the meeting itself, not the solicitation materials, nor is it a DVA as the voting results are not yet declared.
2022-05-11 English
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022 (news with additional features)
AGM Information Classification · 99% confidence The document explicitly announces that the company, Vivoryon Therapeutics N.V., will hold its 'Annual General Meeting on June 22, 2022'. The text contains keywords like 'Annual General Meeting', 'AGM/EGM', and details about the agenda, including the re-appointment of board members. This directly corresponds to the definition of AGM Information (AGM-R). Although it is a news release announcing the meeting, the core subject matter is the AGM itself, making AGM-R the most specific classification over a general RPA or RNS.
2022-05-11 English
Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
Earnings Release Classification · 95% confidence The document is a press release titled 'Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress'. It provides a summary of financial highlights, operational updates, and clinical trial progress. It explicitly states that the full report is available on the company's website, indicating this document is an announcement of the results rather than the full statutory annual report itself. According to the 'Menu vs Meal' rule, this is classified as an Earnings Release (ER). FY 2021
2022-04-28 English
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress (news with additional features)
Earnings Release Classification · 100% confidence The document is titled "Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress" and explicitly states it is announcing financial results for the twelve-month period ending December 31, 2021. It contains detailed sections on 'Financial Results for the Full Year 2021,' including license revenues, R&D expenses, and net loss for the year, along with financial guidance. This content structure is characteristic of an Annual Report or a comprehensive report covering the full fiscal year. Although it is presented as a news release (DGAP-News), the substance is the full annual financial performance summary, which aligns best with the 'Annual Report' category (10-K), even if it is a summary version often released before the formal 10-K filing. Given the comprehensive nature of the financial data provided for the full year, it is classified as 10-K, which covers official yearly reports of full financial performance. FY 2021
2022-04-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.